SMARCA4-DEFICIENT TUMOR
Clinical trials for SMARCA4-DEFICIENT TUMOR explained in plain language.
Never miss a new study
Get alerted when new SMARCA4-DEFICIENT TUMOR trials appear
Sign up with your email to follow new studies for SMARCA4-DEFICIENT TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo targets rare lung cancer in new trial
Disease control Not yet recruitingThis study tests a combination of anlotinib pills and standard chemotherapy for people with a rare, advanced lung cancer that lacks the SMARCA4 gene. About 28 adults will receive the treatment in 21-day cycles to see how long it keeps the cancer from growing and what side effects…
Matched conditions: SMARCA4-DEFICIENT TUMOR
Phase: PHASE2 • Sponsor: Zhijie Wang • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug combo targets rare lung cancer in early trial
Disease control Not yet recruitingThis study tests a new drug combination (iparomlimab and tuvonralimab) plus chemotherapy as a first treatment for people with a rare, advanced lung cancer that lacks the SMARCA4 gene. The goal is to see if this approach can shrink tumors or delay cancer growth. About 28 adults wi…
Matched conditions: SMARCA4-DEFICIENT TUMOR
Phase: PHASE2 • Sponsor: Zhijie Wang • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC